<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="91883">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908829</url>
  </required_header>
  <id_info>
    <org_study_id>905-EC-012</org_study_id>
    <secondary_id>2012-005401-41</secondary_id>
    <nct_id>NCT01908829</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)</brief_title>
  <acronym>BESIDE</acronym>
  <official_title>A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if adding a new type of medication recently approved to
      treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) will be
      more effective in controlling incontinence than when using the antimuscarinic treatment
      alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in mean number of incontinence episodes per 24 hours</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of micturitions per 24 hours</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incontinence episodes reported over 3-day diary</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean volume voided per micturition</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of urgency incontinence episodes per 24 hours</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of urgency incontinence episodes reported over 3-day diary</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of urgency episodes (grade 3 or 4) per 24 hours</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of pads per 24 hours</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pads reported over 3-day diary</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of nocturia Episodes reported in 3-day diary</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of nocturia episodes reported over 3-day diary</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least a 50% decrease from Baseline in mean number of incontinence episodes per 24 hours</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with zero incontinence episodes per 24 hrs at End of Treatment</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a mean of less than 8 micturitions per 24 hours at End of Treatment</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total Euroqol European Quality of Life-5 Dimensions (EQ-5D) score (and subscale scores)</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total OAB-q score (and subscale scores)</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders with at least a 10-point improvement from Baseline in OAB-q subscales</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) score</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Perception Bladder Control (PPBC) score</measure>
    <time_frame>Baseline to end of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least a 1-point improvement from baseline in PPBC</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with major (at least 2-point) improvement from baseline in PPBC</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and Clinician Global Impression of Change Scales (PGIC and CGIC)</measure>
    <time_frame>End of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3815</enrollment>
  <condition>Urinary Bladder Overactive</condition>
  <condition>Urinary Bladder Diseases</condition>
  <condition>Urologic Diseases</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solifenacin succinate low dose plus Mirabegron low dose (first 4 weeks) rising to Mirabegron high dose (for subsequent 8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin succinate low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin succinate high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>YM178,</other_name>
    <other_name>Betanis,</other_name>
    <other_name>Betmiga,</other_name>
    <other_name>Myrbetriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate low dose</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_label>Solifenacin succinate low dose</arm_group_label>
    <other_name>Vesicare,</other_name>
    <other_name>Vesitrim,</other_name>
    <other_name>Vesikur,</other_name>
    <other_name>YM905</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate high dose</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Solifenacin succinate high dose</arm_group_label>
    <other_name>Vesicare,</other_name>
    <other_name>Vesitrim,</other_name>
    <other_name>Vesikur,</other_name>
    <other_name>YM905</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Main Inclusion at Screening:

               1. Subject has symptoms of OAB (urinary frequency and urgency with urgency
                  incontinence) for &gt;= 3 months prior to the screening visit

               2. Subject is willing and able to complete the micturition diary and questionnaires
                  correctly, including collection and measurement of urine output for 3 days prior
                  to each visit;

               3. Subject has symptoms of &quot;wet&quot; OAB (urinary frequency and urgency with
                  incontinence or mixed incontinence with predominant urgency incontinence), and
                  reports an average of at least 2 incontinence episodes per day.

          -  Main Inclusion at Run-in (Visit 2):

               1. Subject experiences on average at least 1 episode of urgency (grade 3 or 4) with
                  or without incontinence per 24-hour period during the 3-day micturition diary
                  period.

               2. Subject experiences on average at least 2 incontinence episodes per 24-hour
                  period during the 3-day micturition diary period.

               3. Subject experiences on average at least 8 micturitions (excluding incontinence
                  episodes) per 24-hour period during the 3-day micturition diary period.

          -  Main Inclusion at Randomization (Visit 3):

               1. Subject experiences at least 1 incontinence episode during the 3-day micturition
                  diary period and wishes to increase their treatment for OAB symptoms.

        Exclusion Criteria:

          -  Main Exclusion at Screening:

               1. Subject in the opinion of the investigator has clinically significant Bladder
                  Outlet Obstruction (BOO).

               2. Subject has significant Post-void residual (PVR) volume (PVR &gt; 150 ml).

               3. Subject has significant stress incontinence or mixed stress/urgency incontinence
                  where stress is the predominant factor as determined by the investigator

               4. Subject has an indwelling catheter or practices intermittent self
                  catheterization.

               5. Subject has evidence of a UTI.

               6. Subject has chronic inflammation such as interstitial cystitis, bladder stones,
                  previous pelvic radiation therapy, or previous or current malignant disease of
                  the pelvic organs

               7. Subject has moderate to severe hepatic impairment

               8. Subject has severe renal impairment or End Stage Renal disease

               9. Subject has a clinically significant abnormal Electrocardiogram (ECG)

              10. Subject has a concurrent malignancy or history of cancer (except noninvasive
                  skin cancer) within the last 5 years prior to screening.

              11. Subject has a QTcF interval &gt; 450 ms for males or &gt; 470 ms for females or is at
                  risk of QT prolongation (e.g., family history of long QT syndrome,
                  hypokalaemia).

              12. Subject has received intravesical treatment in the past 12 months with e.g.,
                  botulinum toxin, resiniferatoxin, capsaicin.

              13. Subject has severe uncontrolled hypertension, which is defined as a sitting
                  average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood
                  pressure ≥ 110 mmHg.

          -  Main Exclusion at Randomization (visit 3):

               1. Subject has achieved 100% continence from Visit 2 to Visit 3 (no incontinence
                  episodes are recorded in the 3 day diary administered for 3 days prior to Visit
                  3).

               2. Subject does not desire an increase in study medication.

               3. Subject has an average total daily urine volume &gt; 3000ml as recorded in the
                  micturition diary.

               4. Subject has severe uncontrolled hypertension, which is defined as a sitting
                  average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood
                  pressure ≥ 110 mmHg.

               5. Subject has a clinically significant abnormal ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genova Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Pharmaceutical Research Center, Inc.</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The American Institute of Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West FL</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Quality Research Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Professional Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Center of Central Florida</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herman Clinical Research</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Idaho Urology</name>
      <address>
        <city>Coeur D'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Gateway Health Center</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay State Clinical Trials, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Centers of New York</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley PC</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, dba PMG Research of Cary</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Urology Specialists</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Partners</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandria Clinical Research</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 37402</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 37403</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 37405</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 61006</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 61001</name>
      <address>
        <city>Kogarah, Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 61016</name>
      <address>
        <city>Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43008</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43001</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43006</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43007</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43002</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43004</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43005</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43010</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43011</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43012</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43003</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32007</name>
      <address>
        <city>Anderlecht</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32013</name>
      <address>
        <city>Deurne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32009</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32003</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32005</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32015</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32008</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32014</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15001</name>
      <address>
        <city>Barrie</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15009</name>
      <address>
        <city>Bathurst</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15006</name>
      <address>
        <city>Brampton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15015</name>
      <address>
        <city>Granby</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15014</name>
      <address>
        <city>Kelowna</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15007</name>
      <address>
        <city>Kitchener</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15019</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15012</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15013</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15018</name>
      <address>
        <city>Victoriaville</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15016</name>
      <address>
        <city>Victoria</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 15047</name>
      <address>
        <city>Victoria</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42015</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42020</name>
      <address>
        <city>Melnik</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42018</name>
      <address>
        <city>Nachod</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42004</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42021</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42016</name>
      <address>
        <city>Prague 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42008</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42017</name>
      <address>
        <city>Praha 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42007</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42022</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 45008</name>
      <address>
        <city>Aarhus N</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 45003</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 45009</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 45011</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35804</name>
      <address>
        <city>Helsinki (HUS)</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35805</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 33018</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 33017</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 99502</name>
      <address>
        <city>T'bilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49008</name>
      <address>
        <city>Bad Ems</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49022</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49021</name>
      <address>
        <city>Hagenow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49011</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49004</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49018</name>
      <address>
        <city>Henningsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49009</name>
      <address>
        <city>Hettstedt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49017</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49003</name>
      <address>
        <city>Lutherstadt Eisleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49020</name>
      <address>
        <city>Reutlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 49014</name>
      <address>
        <city>Sangerhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 30001</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 30005</name>
      <address>
        <city>Heraklion, Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 30002</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 36003</name>
      <address>
        <city>Csongrad</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 36011</name>
      <address>
        <city>Hajduszoboszlo</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 36002</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 36008</name>
      <address>
        <city>Salgotarjan</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 36009</name>
      <address>
        <city>Szekszard</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35303</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35301</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35309</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35310</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35306</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35313</name>
      <address>
        <city>Mullingar</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35304</name>
      <address>
        <city>Tralee</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35305</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 97201</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 97202</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 97207</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 97203</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 97205</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 97206</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 39007</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 39002</name>
      <address>
        <city>Cantanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 39010</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 39006</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 39013</name>
      <address>
        <city>Treviglio (BG)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 39009</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 96101</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 31008</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 47005</name>
      <address>
        <city>Bekkestua</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 47002</name>
      <address>
        <city>Tonsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 47003</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 48002</name>
      <address>
        <city>Kolbuszowa Dolna</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 48006</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 48010</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 48005</name>
      <address>
        <city>Piaseczno</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 48001</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 48008</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35104</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35105</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35102</name>
      <address>
        <city>Matosinhos</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35103</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35101</name>
      <address>
        <city>Setubal</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35106</name>
      <address>
        <city>Tomar</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 40016</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 40018</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 40012</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 40019</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 40003</name>
      <address>
        <city>Judetul Ilfov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 40017</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 40020</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70003</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70004</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70005</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70008</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70010</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70011</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70012</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70024</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70013</name>
      <address>
        <city>Rostove-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70002</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70006</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70007</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70009</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 70025</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42110</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42114</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42113</name>
      <address>
        <city>Michalovce</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42111</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42112</name>
      <address>
        <city>Piestany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42108</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42109</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 38601</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 38606</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 38607</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 38610</name>
      <address>
        <city>Ptuj</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34012</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34016</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34001</name>
      <address>
        <city>Getafe (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34004</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34015</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34023</name>
      <address>
        <city>Mendaro</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34021</name>
      <address>
        <city>Miranda de Ebro</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34018</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34013</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34007</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34020</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34014</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 46004</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 46013</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 46014</name>
      <address>
        <city>Norrtalje</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 46001</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 46012</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 46015</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 41008</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 41001</name>
      <address>
        <city>Frauenfeld</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 90005</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 90008</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 90002</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 90003</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 90007</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 90004</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 90006</name>
      <address>
        <city>Sivas</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44007</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44012</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44015</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44019</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44009</name>
      <address>
        <city>Garston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44016</name>
      <address>
        <city>Kings Lynn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44017</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44018</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44010</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44008</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44013</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 44011</name>
      <address>
        <city>West Yorkshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Egypt</country>
    <country>Jordan</country>
    <country>Kazakhstan</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 20, 2015</lastchanged_date>
  <firstreceived_date>July 24, 2013</firstreceived_date>
  <firstreceived_results_disposition_date>August 12, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder (OAB)</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>Urgency incontinence</keyword>
  <keyword>Frequency</keyword>
  <keyword>Urgency</keyword>
  <keyword>Micturition</keyword>
  <keyword>YM178</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Solifenacin</keyword>
  <keyword>Betmiga</keyword>
  <keyword>Myrbetriq</keyword>
  <keyword>Betanis</keyword>
  <keyword>Vesicare</keyword>
  <keyword>Vesitrim</keyword>
  <keyword>Vesikur</keyword>
  <keyword>YM905</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Diseases</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
